Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2016—Thermo Fisher Scientific launched Applied Biosystems TaqPath 1-Step Multiplex PCR Master Mix, a preformulated, universal, 4× concentration master mix designed to deliver sensitive and reproducible detection of up to four RNA (or DNA) targets in a single multiplex reaction.
June 2016—Phoenix-based Cyrex Laboratories, a clinical immunology laboratory specializing in functional immunology and autoimmunity, was awarded a Medical Device Establishment License by Health Canada and can now service the Canadian market through licensed health care professionals.
June 2016—BioTek Instruments launched the Lionheart FX Automated Live Cell Imager with Augmented Microscopy. Lionheart FX is optimized for kinetic live cell imaging, with up to 100× air and oil immersion magnification in a variety of slides, dishes, microplates, and flasks.
June 2016—Eurofins Scientific has acquired PerkinElmer’s U.S. prenatal screening laboratory services business, PerkinElmer Labs/NTD.
June 2016—MedTest announced the availability of a 25-OH Vitamin D Assay for the BS-480 chemistry analyzer. MedTest is the exclusive U.S. distributor of the BS-480 analyzer including manufacturing and distribution of reagents, calibrators, and quality control products for the general chemistry and drugs of abuse testing markets in the United States and Canada.
June 2016—BD Biosciences introduced the BD Accuri C6 Plus flow cytometer. This new cytometer has several optimized enhancements to the internal hardware, fluidics, and software while maintaining the core elements of the prior platform such as the nonpressurized peristaltic pump system and compact exterior design.
June 2016—MDxHealth announced the commercial launch of its SelectMDx for Prostate Cancer test in the U.S. as a laboratory developed test. Testing will be conducted at MDxHealth’s CAP- and CLIA-accredited laboratory facilities in Irvine, Calif.
June 2016—HTG Molecular Diagnostics entered into a research collaboration agreement with Bristol-Myers Squibb to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types.
June 2016—The AIA-900 Benchtop model is now available from Tosoh. The AIA-900 uses Tosoh’s Unit Dose Test Cup reagent technology. Single, unitized test cups do not require premixing, premeasuring, or onboard refrigeration. The AIA-Pack test cup format works with every Tosoh AIA automated immunoassay system. Reagents are interchangeable, so laboratories with more than one Tosoh system can use the same reagents.
June 2016—SeraCare Life Sciences launched an expanded product line to support NGS-based somatic tumor profiling assay development, validation, and QC performance monitoring. The eight new Seraseq Solid Tumor Mutation Mix-II products contain 40 somatic variants with increases in the number of insertion-deletion mutations from four to 13 to challenge both the sequencing and variant calling algorithms.
